Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus
erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it …

Abstract Coronavirus disease 2019 (COVID-19) pandemic has become challenging even for
the most durable healthcare systems. It seems that vaccination, one of the most effective …

Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …

Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …

Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become
a high priority. Persons at risk of severe disease, for example, those receiving …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

The first EULAR provisional recommendations on the management of rheumatic and
musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

The provisional EULAR recommendations address several aspects of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by …

Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 …